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Metastatic bone disease  







Regardless of prognosis, surgery is often considered in metastatic bone disease (MBD) as a 
palliative procedure to improve function and quality of life.  Traditional focus on objective 
outcomes such as mortality is inappropriate in this group, and there is a drive to assess 
outcomes via patient-reported outcome measures (PROMs).  This is an overview of current 
understanding of MBD outcomes and how this should influence future decision-making and 
direct research. 
The objectives of this review were to identify difficulties in measuring PROMs in the MBD 
patient population and explore alternatives to patient-reported outcomes.  We also provide 
an overview of current understanding of outcomes in MBD and how this should influence 









MBD affects 40-70% of patients with solid organ malignancies, more commonly in  breast and 
prostate cancer(1), and up to 95% of patients with multiple myeloma(2, 3).  The presence of 
widespread bony secondaries in systemic cancer is considered an incurable stage of the 
disease but surgery is often indicated to restore function, independence and relieve pain(4, 
5).  However, there is widespread variation in surgical practice(6), and no consistent means 
of assessing outcomes in this patient group.(4, 7). 
Historically, orthopaedic surgery  focused on measures such as mortality, complications and 
revision surgery to assess outcomes after surgery(8, 9).  However, as early mortality can be 
high in this group(10) and patients may not be fit for revision(11), a more recent focus has 
been PROMs(9). 
Using PROMs allows patients to express their outcome in terms of function and quality of life 
without interpretation by their care provider(12).  However, widespread measurement of 
PROMs in MBD has been slow to materialise for many reasons, including: 
• Challenge of defining the goal of treatment in MBD 
• Burden of participation for these multi-morbid patients(13) 
• Widespread variation and inconsistency in use of PROMs for MBD(5) 
 
The aim of this review was to assess PROMs in terms of quality of life, function and pain relief 
after surgery for MBD. 
 
 
What outcomes are important to patients with MBD? 
 
PROMs can measure any parameter of patient outcome after treatment, and usually (but not 
exclusively) cover outcomes that are difficult to measure objectively, such as quality of life 
(QOL) and function(2, 14).  This is particularly important in MBD since many of the available 
treatments are given with the intention to relieve symptoms and maximise quality of life (with 
type of surgery determined through consideration for a patient’s prognosis, risk of 
complications and likely outcome from surgery)(3, 15).  In a palliative condition like MBD, 
quality of life and symptom control are arguably more meaningful and fairer methods of 
outcome measurement than mortality or revision rate(16, 17).  
 
Skeletal-related events (SREs) secondary to MBD (such as pathological fractures and spinal 
cord compression) can cause pain, loss of function and a reduced quality of life(18, 19).  
However, MBD treatments such as radiotherapy and pain-reducing surgery can also lead to 
negative effects on patient outcome, trading function for pain relief(19).  In order to fairly 
measure patient-reported outcomes after surgery for MBD, we have to consider what 
outcomes patients prioritise in their care and rehabilitation.  This is a difficult task because 
relevant outcomes from treatment in MBD can vary widely between different individuals.  For 
example, the patient with metastatic breast cancer in their fifties with a young family and a 
prognosis of years may have very different expectations than the frail patient in their eighties 
with lung cancer and a prognosis of weeks.  However, as a result of improved systemic 
therapies, more and more people are living longer with bone metastases and our priority for 
every patient should be to maximise their quality of life for the time remaining to them(20). 
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Mougalian and colleagues asked patients with metastatic breast cancer about the PROMs 
that were important to them and identified five domains that were negatively affected by 
systemic cancer: physical, psychological, function/mobility, social, financial and treatment-
related(13) (Table 1).  There was significant variation when participants were asked to rank 
domains by importance, but the most commonly ranked priorities included physical 
symptoms (such as fatigue and nausea), treatment burden (including visit frequency and 
invasive procedures) and emotional impact of cancer (including anxiety and depression)(13).   
 
During development of the EORTC BM22, one of the few PROMs validated in MBD, Chow and 
colleagues noted that feedback from patients was strongly in favour of pain as the primary 
symptom of importance in MBD(16).  Although treatments such as radiotherapy can 
temporarily reduce other parameters such as mobility and function, the researchers noted 
that disabilities related to severe pain such as the inability to walk could be improved or even 
restored through adequate pain relief in many cases(13, 16).  In short, each of the key 
outcomes in MBD are interconnected, and any method for measuring them has to take this 
into account. 
 
In addition, data collection should not solely focus on the period of inpatient care.  In a 
progressive condition like MBD, function and quality of life can deteriorate after discharge(21) 
due to disease progression, metalwork failure, infection and other correctable complications 
of surgery.  Many of these patients are deliberately not seen postoperatively, in an attempt 
to minimise burden of hospital visits and let patients ‘get on with their life’.  Even when follow-
up is planned, there is a high attrition rate due to patient morbidity and mortality(22).   
 
What PROMs do we have for MBD? 
 
MBD-specific PROMs have traditionally been lacking, and this impacts on the interpretation 
of some of the older studies in the literature(5, 20).  With the invention of more recent specific 
instruments such as the EORTC-QLQ BM22(16) and BOMET-QOL(3), data collection has 
become more reliable and specific.  Table 2 summarises the most commonly utilised PROMs 
in MBD, and demonstrates which scoring systems are non-specific and which are validated in 
patients with bone metastases. 
 
Pain 
Pain assessment is a key focus of outcome measurement in MBD as both an objective 
measure (e.g. analgesia use), and as the most frequently reported contributor to poor 
function and quality of life(23).  As summarised in the excellent 2006 paper by Cleeland and 
colleagues, there is no single pain assessment instrument which can assess all of the facets of 
pain experienced by cancer patients AND account for the additional trauma of a pathological 
fracture(24).  However, we would recommend the Functional Assessment of Cancer Therapy-
Bone Pain (FACT-BP) as it has been validated for use in the metastatic cancer population(25, 
26). 
 
Function & mobility 
Function is a key outcome in musculoskeletal patients and is defined separately, but with 
significant overlap, to quality of life.  Although both describe an individual’s ability to live the 
life they would choose, we have defined function as the effect of cancer symptoms on a 
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patient’s “physical ability to perform tasks and roles”, and quality of life as the more rounded 
“ability to participate in their chosen lifestyle”.  Two musculoskeletal oncology scores which 
have been validated for use in MBD patients are the Musculoskeletal Tumor Society (MSTS) 
functional assessment form(27) and the Toronto Extremity Salvage Score (TESS)(28).  The 
MSTS score was originally developed as a physician-reported score but has been validated for 
use as reported by patients (29).  Both scores have upper and lower limb-specific variations 
and although the MSTS has a lower precision than the TESS, it takes significantly less time for 
participants to complete, a key factor in maximising adherence(30).  
Largely comparable to the MSTS and TESS is an adaptive questionnaire, the Patient-Reported 
Outcomes Measurement System (PROMIS)(30).  The PROMIS questionnaire is delivered 
electronically and adapts according to each answer given, leading to a significantly shorter 
time for completion(30, 31).  Depending on the availability of electronic means of data 
collection and capture to research teams, this may be a less burdensome option for 
measuring PROMs in MBD. 
 
Quality of life  
Quality of life is commonly taken to cover many of the above terms and comprises the degree 
to which all of the above interact to allow a patient to live according to their own wishes.  The 
European Organisation for Research and the Treatment of Cancer Quality of Life 
questionnaire (EORTC-QLQ C-30) is the most commonly used measure of quality of life in 
studies on patients with cancer(8, 20).  In order to address additional bone metastasis-specific 
issues such as pathological fractures, the EORTC module BM22 was developed in 2009 and is 
usually administered along with the full EORTC questionnaire(16, 25).   
 
Mood and physical symptoms 
No specific tools exist for measuring mood or physical cancer symptoms in MBD.  Such aspects 
of patient outcome are incorporated in larger scores such as the EORTC QLQ-C30 
questionnaire or non-specific tools such as the Hospital Anxiety and Depression score 
(HADS)(32) or Edmonton Symptom Assessment System (ESAS)(33) can be utilised. 
 
 
What are the difficulties in measuring PROMs in MBD? 
 
In seeking to improve PROM reporting in MBD, there are several key difficulties to address.  
The PROM should measure the most clinically appropriate endpoint in determining outcome, 
the burden of participation for such a multi-morbid group should be considered, and the score 
should reflect the rapidly changing population with systemic cancer. 
 
Does the PROM measure the most clinically appropriate outcome? 
Total knee replacements (TKRs) have long been held as an example of the discrepancy 
between the utility of PROMs in discriminating successful from unsuccessful surgery.  
Although TKR can be expected to provide excellent pain relief, dissatisfaction rates range from 
10-33% and residual functional symptoms range from 33-54%(34-37).  This is considered 
acceptable as long as patients are adequately counselled, and is not a valid argument for 
refusing to perform TKR on patients with an appropriate level of pain(9).  As a result, PROMs 
used in outcome-measurement should be the most appropriate ones to reflect the reason for 
surgery (i.e. pain relief) with appropriate pre-operative counselling of patients regarding both 
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positive and negative effects of surgery(9, 35).  This is particularly relevant in the case of 
patients undergoing surgery for MBD, as this is rarely life-prolonging, but intended to relieve 
pain and improve function.  We have already discussed key outcomes which patients with 
MBD find important, and these include physical symptoms such as pain and disability, 
treatment burden and the emotional impact of secondary bone cancer(13). 
 
Burden of participation for patients with MBD 
Another difficulty in mass uptake of PROMs for the MBD population is the participation 
burden.  Patients referred to orthopaedics with a bony metastasis in the proximal femur have 
a mean age of 72 years, a 90-day mortality of 46% and are often under the care of multiple 
specialities (10).  With the added disability of a pathological fracture, this population may 
have difficulty completing paper forms, attending clinic appointments and who may tire more 
easily than patients with traumatic fractures.   
Prospective studies looking to assess PROMs should minimise participant burden to reduce 
this risk.  Questionnaires should be kept short and relevant, with prioritisation of the key 
outcome measures based on prior patient-involvement and statistical planning(38).  Options 
to overcome physical barriers such as disability and pain might include recording equipment 
(to minimise the need for writing) or consultations via email or telephone (to minimise the 
need to attend physical appointments)(14, 38).  Use of proxy data collection by a family 
member or friend can be used selectively, and there is some evidence that questionnaires 
such as the EORTC-QLQ C-30 show reasonable consistency between patient- and proxy-
reported PROMs (8).  Finally, adaptive PROMs such as the PROMIS score(30) are gaining 
popularity, particularly in frailer patient groups.  Adaptive PROMs target questions based on 
previous answers, and can be significantly quicker, easier and more precise to use(9, 30).  
There is evidence that these scores can help to include older patients or those with language 
barriers(8, 39), but they do require the use of electronic devices, which can be expensive or 
impractical(9).  
 
Do PROM scores reflect changing population? 
Thanks to improving systemic therapies for malignancy, patients with MBD are now living 
longer with a lower disease-burden(40).  Although many MBD patients are elderly and frail 
with prognosis measured in months(10), there is an increasing subgroup of younger, fitter 
patients with a better prognosis and expectations of surgery beyond simple pain relief.  
PROMs used in MBD need to accurately reflect patients at both ends of this spectrum(9). 
Despite the immediate beneficial effect of surgery for MBD, there is the potential for 
deterioration over the postoperative course due to progression of the underlying disease.  
This could mask the beneficial outcomes of surgery and PROMs used should focus on pain 
relief at the site of surgery or prevention of pathological fracture in those undergoing 
prophylactic stabilisation (5).   
Another vital factor is analysing for the presence of floor/ceiling effects.  If the scores used 
are not sensitive enough, they will fail to differentiate between patients scoring highly at the 
top of a score (ceiling) or fail to detect subtle problems in those scoring very poorly (floor 
effect)(41).  Many of the PROMs in use have traditionally focused on differentiation between 
patients scoring poorly in terms of pain, function and quality of life, but the problem of ceiling 
effect will become more marked as we treat younger, fitter patients with a better prognosis.   
Studies should focus on outcomes in both specialist tumour- and unselected trauma centres 
to ensure the whole range of patients with MBD are included in PROM studies.  In addition, 
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patients should be followed up for a clinically relevant timeframe (Ernest Codman’s ‘end 
result’ principle, whereby patients must be followed up for long enough to measure the 
appropriate clinical outcomes) and change in trend over time prioritised over cross-sectional 
outcome studies(9, 42). 
 
 
Alternatives to PROMs 
 
Subjective outcome measurement is important in MBD to reflect the efficacy of healthcare 
interventions (in terms of improvement in pain, mobility and quality of life) when surgery is 
rarely a life-prolonging undertaking.  However, there are alternatives to PROMs, as 
summarised in Table 3.  These include performance-based outcome measures, physician-
reported outcome measures and quality indicators of outcome.  However, the majority of 
these do not incorporate the outcomes that are considered by patients to be important to 
them, and none are able to capture patient perspective on MBD surgery. 
 
 
What do PROMs show in MBD? 
 
Cheng’s 2003 review provides a descriptive baseline on PROMs in MBD up until 2001(5).  
Cheng remarked that most studies were retrospective or cross-sectional, with inconsistent 
use of PROMs that were not specific to bone metastases (5).  They did find early evidence 
that most patients appear to benefit from surgery, but found it difficult to quantify this 
improvement due to the variation in PROMs utilised.  This section will summarise what is 
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Pain 
Pain is the commonest symptom associated with MBD and is reported by 50-90% of 
patients(16, 43).  Pain is caused by involvement of weight-bearing cortical bone and 
exacerbation can predict impending pathological fractures(44).  Pain severity is higher in 
patients with multiple metastases but tends to be less severe in some primaries such as 
lymphoma and prostate cancer(45).   
Analgesic use as an objective measure of pain is frequently used but often poorly 
quantified(23).  Talbot and colleagues found a significant reduction in post-operative pain 
scores at 6 and 12 weeks post-surgery for MBD, but failed to show a statistically significant 
difference in the pre- and 3-month post-op analgesic use of 84% and 67%, respectively(22).  
This may reflect the relatively small sample size of the cohort (67 patients) or the effect of 
outliers. 
The cross-sectional nature of most of the available studies neglects to explore concerns about 
deterioration after surgery due to disease progression.  A small study that explored this in 
terms of pain relief (n=13) showed an improvement in pain scores after internal fixation or 
arthroplasty for MBD(31).  This plateaued between post-operative weeks 12-20 then fell at 6 
months, the last follow-up point(31).  A much larger study published the same year (n=184) 
demonstrated a sustained improvement in pain scores at one year post-surgery measured 
through the non-specific BPI tool(46).  Therefore, although evidence in the literature is 
currently lacking to demonstrate a specific and sustained improvement in localised pain after 
surgery for MBD, it seems reasonable to conclude that there is no evidence to suggest pain 
relief is only short-lived after surgery for MBD. 
Finally, there is some evidence that the type of surgical procedure influences post-operative 
pain in MBD.  Although no studies have demonstrated a clear difference between methods 
of internal fixation, arthroplasty or endoprosthetic reconstruction (EPR), a 2010 study of 87 
patients comparing IMN and EPR demonstrated similar levels of post-operative pain relief 
(measured through the MSTS bone tumour-specific PROM) at a median follow-up of 8 
months(47).   
 
Function/mobility 
Poorer outcome in terms of function is associated with a number of patient variables in MBD, 
including increasing age, pain severity, medical comorbidities and female gender (in one 
study)(43, 45, 48).   There is some evidence for better function in those with prostate/thyroid 
primaries and in those who survive more than 12 months after surgery(45, 49).  Perhaps 
surprisingly, there is no significant difference in function for those who did or did not sustain 
a pathological fracture (mean MSTS 66% for those with fractures versus 67% for those 
without)(50). 
Weightbearing status is infrequently recorded, but reported as 72% of EPR patients during 
the immediate post-operative period(51).  The only study to record medium-term 
weightbearing status was Furtado’s 2015 study on amputation for lower extremity bone 
tumours (not specific to metastases) which reported a 70% dependence on walking aids at 12 
months(43). 
Most studies show a continued improvement up to one year in function/mobility as assessed 
by the MSTS and TESS scores(22, 46, 47, 52).  Where quantified, MSTS outcomes range from 
15-47% (preoperative values) to 73-90% (8-12 months post-op) (22, 46, 47, 52) and TESS 
values ranged from 40-44% (preoperative) to 63-75% (3-12 months post-op)(22, 52).  Park et 
al.’s 2007 paper studied patients at a single point from surgery and found high function rates  
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measured through MSTS (mean 73%, range 57-90%) and TESS (mean 71%, range 46-95%) at 
an average of 48 months post-surgery(53). 
There is conflicting evidence in the literature for any difference in function between the less 
invasive internal fixation surgical options (e.g. intramedullary nail IMN) compared to excision 
and EPR.  Two studies investigating functional outcome in humeral metastases showed 
conflicting results, with Bickels and colleagues demonstrating better outcomes in diaphyseal 
metastases fixed with cemented IMN (mean MSTS 85-100%, n=31) compared to EPR of peri-
articular metastases (mean MSTS 70-97%, n=17) at a median follow-up of 1.7 years(54).  In 
contrast, Piccioli’s 2010 study showed a difference in mean MSTS of 73% and 79% in favour 
of EPR at a median 8 months follow-up(47).  In a large study comparing methods of lower 
limb reconstruction for proximal femoral metastases (n=158), Harvey and colleagues 
demonstrated a difference in mean MSTS of 70% for IMN and 80% for EPR at a mean follow-
up of 16 months, but this did not reach statistical significance(55).   
We would conclude that although there is conflicting evidence, post-operative function 
appears to be relatively well restored in all surgical options.  The choice for type of 
reconstruction should be taken based on patient comorbidities, cancer prognosis and with an 
understanding of the additional risks of EPR. 
 
Quality of life 
Quality of life (QOL) in MBD has been largely under-researched in favour of other PROMs such 
as function and pain relief.  Where QOL has been investigated and found to be low 
postoperatively, this has been attributed to the effects of treatment or cancer progression 
without formal exploration(46).  Chow and colleagues published a large study in 2018 (n=298) 
investigating the effect of palliative radiotherapy on quality of life measured using the BM22 
in patients with bone metastases(48).  This demonstrated that younger patients tended to 
report a poorer baseline quality of life score with more severe treatment-related symptoms 
of nausea and vomiting compared to elderly patients(48).  Patients showed an improvement 
at 42 days post-treatment in all realms of the EORTC BM22 (painful sites, pain characteristics, 
functional interference and psychosocial aspects of symptoms) ranging from 3-16%, but 
required a minimum of 10% change to consider improvement a clinically relevant change(48).  
The short follow-up duration of this study limits any other conclusions being drawn. 
Only two studies investigated QoL after surgery for MBD.  These both showed no difference 
in the Short Form 36 up to 3 months(22) or the QOLLTI-P at up to one year post-surgery(46). 
We would conclude that there is a requirement for further prospective studies investigating 
outcomes in terms of quality of life in the MBD population.  These studies should follow up 
patients to a clinically relevant outcome, at least 3-6 months from surgery (12 months after 
EPR) and should utilise a MBD-specific outcome score, such as the EORTC-QLQ BM22(16). 
 
Psychosocial 
None of the studies reviewed explored the effect of surgery for MBD on psychosocial aspects 
of treatment such as mood, anxiety and depression.  Improving pain is associated with 
reduced depression scores in cancer patients(56) but this is an area which remains under-
represented in the literature and requires specific exploration. 
 
To summarise, current studies in the literature exploring patient reported-outcomes in MBD 
tend to be retrospective or cross-sectional, small in sample size and are inconsistent in terms 
of the scoring systems used.  Many of these are not MBD-specific, although this has improved 
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in the last ten years in some areas such as function.  Current studies neglect to investigate 
factors associated with good or poor outcome, and neglect quality of life and psychosocial 
outcome as key aspects of care. 
 
 
How should PROMs influence clinical decision-making? 
 
Finally, we will address whether PROM scores should be utilised in controlling access to 
surgery, how they can improve patient care (including measuring the impact of new 
treatments) and the practicalities of measuring PROMs on a national scale with inclusion in 
data registries. 
 
Access to surgery 
Recently, there has been considerable interest in the use of PROMs to prioritise or control 
access to surgery(9, 57, 58).  Despite the fact that PROMs were initially designed to compare 
the benefit of different treatments, approaches or implants for a specified condition, they 
have increasingly been used on a regional basis (particularly in the UK) to guide health boards 
in prioritising and offering surgery for life-enhancing but not prolonging procedures, such as 
hip and knee replacements(9, 59).  The main argument for use of PROMs in controlling access 
to surgery is the increased focus this places on life-enhancing outcomes over objective 
outcomes such as survival and length of hospital stay(9).  However, arguments against PROM-
related health rationing include concerns about local ‘postcode lotteries’ and risk of bias 
against vulnerable patients because of the documented relationship between poor 
preoperative health, function and mental health status, and poor postoperative outcome(9, 
58, 59).  In their excellent 2011 study, Judge and colleagues demonstrated that patients with 
better preoperative functional scores were more satisfied with their surgery, and concluded 
that preoperative PROM scores cannot reliably predict surgical outcome(9, 60). 
Similar difficulties can be expected in MBD, whereby there is insufficient evidence at present 
to support the benefits of variation in care (such as more or less invasive surgery) and 
inadequate evidence-based thresholds for benefit from surgery according to patient gender, 
health status and prognosis(45, 55).  For surgery to be deemed successful in MBD, patients 
must experience pain relief, an improvement in function and satisfaction with the 
procedure(58, 61).  We would recommend that the role for PROMs in MBD is not in 
determining the severity of symptoms that should be present before surgery is undertaken 
but in quantifying benefit and comparing any treatments available(58, 62). 
 
Using PROMs to improve patient care 
The routine use of PROMs in clinical settings can lead to improvements in patient care, 
satisfaction and even prolong survival(13, 14, 63).  The results from PROM studies have 
demonstrated benefit from surgery in terms of pain relief, function and quality of life, and 
have been used to compare and contrast current interventions such as IMN versus EPR(47, 
54).  In addition, PROMs can be used to test and validate new treatments in MBD, where no 
survival advantage is expected but efficacy is quantified in terms of functional or quality of 
life outcome(8, 14). 
 
Inclusion of PROM data on national registries 
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Finally, PROMS can be used to drive service improvement at the national and international 
levels via inclusion on data registries(14).  Breakwell’s 2015 “Should we all go to the PROM?” 
editorial covering the first two years of the British Spine Registry provides an excellent 
overview of the benefits of including PROM data on data registries, which include enhancing 
quality of care, multi-centre comparison of clinically-relevant outcomes and the move 
towards ‘value-based healthcare’ (64).  Barriers to this include the significant local variation 
with different PROMs used by different centres, perception of burden of inclusion from 
participating clinicians and cost (14, 64).  The PROMIS score was developed by the National 
Institute of Health (NIH) to address inconsistencies between different PROM scores(65). 
 
Conclusions and future directions 
 
In conclusion, PROMs should be prioritised in outcome-assessment after surgery for MBD 
because they reflect the changes in QOL and function that are the key indication for surgery 
in this group.  Oncological procedures such as tumour excision and EPR can be invasive 
procedures with a significant morbidity(55), so they should only be undertaken when the 
balance of potential benefit is favourable for individual patients.  Assessing patient-reported 
outcomes is the best way to determine this. 
Controversies in uptake of PROM-measurement in orthopaedics include concerns at using 
PROMs to control access to surgery.  We do not recommend this and suggest that PROMs 
should be used to compare current and novel treatments and not to determine the overall 
success of a procedure.  Alternatives to PROMS such as physician-reported measures and QIs 
have advantages and disadvantages, and PROM measurement should be used to complement 
other clinical parameters including objective outcome measurement(14). 
The difficulties in measuring PROMs in the MBD population include participant burden and 
the need to ascertain the outcomes of importance to individual patients.  Concerns have been 
raised that deteriorating function or pain relief over time would provide evidence against 
surgery in MBD, but there is no evidence to support this. 
Future studies incorporating PROMs in outcome-assessment for patients with bone 
metastases should use measures specific to this population and measure additional outcomes 
as a ‘sense check’(66).  To ensure the most relevant outcomes to patients are being assessed, 








Table 1 – What outcomes do MBD patients consider important? 
 
Domain Example 
Physical Pain, fatigue, nausea, energy, loss of appetite(67) 
Psychological Depression, ability to cope, health perception(68) 
Function/mobility Ambulation, continence(21) 
Social Loneliness, sexual function 
Financial Treatment expenses, travelling to appointments 
Treatment-
related 
Treatment burden (e.g. frequency of visits, number of blood draws 
etc), skeletal-related events (SREs, e.g. fractures, 
hypercalcaemia)(20) 
Adapted from Mougalian et al.(13) 
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Table 2 – Overview of patient-reported outcome measures (PROMs) in metastatic bone 
disease (MBD) 
 
 Non-specific Validated in MBD/orthopaedic oncology 
Pain 
Brief Pain Inventory Short-
Form (BPI-SF)(69)  
McGill Pain Questionnaire 
Short-Form (MPQ-SF)(70) 





Karnofsky Performance Score 
(KPS)(2) 
Eastern Cooperative Oncology 
Group (ECOG)(71)  
Musculoskeletal Tumor Society 
score (MSTS)(27) 
Toronto Extremity Salvage score 
(TESS)(28, 72) 
Patient-Reported Outcomes 
Measurement System (PROMIS) 
Physical Function score(30) 




Hospital anxiety and 












Patient-reported assessment of outcome after surgery for bone metastases 
 13 
Table 3 – Comparison of objective methods of outcome assessment 
 





-Easy to measure 
-Infrastructure already in place 
to record these 
-May not be appropriate in 
the MBD population 
Performance-based 
outcome measures 
-Improved sensitivity versus 
PROMs e.g. ability to distinguish 
pain from function(73) 
-Improved validity to PROMs(9) 
-Don’t show ceiling effects(9) 
-Ecological validity – do they 
measure real-world 
function?(9) 
-Hawthorne effect: participant 
acts differently because they 
are being observed(73, 74) 
Physician-reported 
outcome measures 
-Gold standard for measuring 
function(9) 
-Measure objective surgical 
outcomes e.g. strength, range of 
movement (ROM)(57) 
-Minimise ceiling effects(9) 
-No educational/language 
barriers 
-Expensive and not broadly 
available(9) 
-Doesn’t necessarily take into 
account outcomes important 
to patients 
-Clinicians overestimate 
outcome vs patients(30) 
-Poor inter-observer 
reliability(73) 
Quality indicators of 
treatment outcome 
-Allow comparison between 
different centres/countries(8, 
75) 
-Can be used to identify 
complex patients who may 
benefit from tertiary 
orthopaedic oncology 
opinion(76) 
-Significant effort required to 
develop(77) 
-Need to be validated for 
specific population(77) 
-Constantly changing(78) 
-Can only measure outcomes 
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